| Triamcinolone Acetonide Topical Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Triamcinolone Acetonide Topical 0.025% | ointment | topical | 100.0 gram(s) | OTC |
| Triamcinolone Acetonide Topical 0.1% | ointment | topical | 100.0 gram(s) | OTC |
| Triamcinolone Acetonide Topical 0.5% | ointment | topical | 100.0 gram(s) | OTC |
| Triamcinolone Acetonide Topical 0.025% | lotion | topical | 100.0 milliliter(s) | OTC |
| Triamcinolone Acetonide Topical 0.1% | lotion | topical | 100.0 milliliter(s) | OTC |
| Triamcinolone Acetonide Topical 0.5% | cream | topical | 100.0 gram(s) | OTC |
| Triamcinolone Acetonide Topical 0.1% | cream | topical | 100.0 gram(s) | OTC |
| Triamcinolone Acetonide Topical 0.025% | cream | topical | 100.0 gram(s) | OTC |
| Triamcinolone Acetonide Topical 0.1% | paste | mucous membrane | 100.0 gram(s) | OTC |
Echo Therapeutics Announces Closing of Approximately $2.3 Million ... - FOXBusiness
Durhalieve(TM), Echo's lead AzoneTS drug candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid ...
Wed Feb 13 14:14:56 -0500 2008
Echo Therapeutics Announces Closing of Approximately $2.3 Million ... - PR Newswire (press release)
Durhalieve(TM), Echo's lead AzoneTS drug candidate, is an advanced topical reformulation of triamcinolone acetonide for treatment of corticosteroid ...
Tue Feb 12 18:06:42 -0500 2008
Wendy Ann Satmary, MD, Kaiser Permanente Medical Center, Woodland ... - AAFP News Now
... 5 to 20 mg of triamcinolone acetonide (Kenalog) can be injected directly into the area, and cryotherapy can be performed using the contact method, ...
Wed Jan 30 11:56:11 -0500 2008
triamcinolone acetonide - The acetonide salt form of triamcinolone, a synthetic glucocorticosteroid with immunosuppressive and anti-inflammatory activity. Triamcinolone acetonide binds to specific cytosolic glucocorticoid receptors and subsequently interacts with glucocorticoid receptor response element on DNA and alters gene expression. This results in an induction of the synthesis of certain anti-inflammatory proteins while inhibiting the synthesis of certain inflammatory mediators. Consequently, an overall reduction in chronic inflammation and autoimmune reactions are accomplished.